Showing 5171-5180 of 8843 results for "".
- Meet truSculpt flex: Cutera’s Solution for Toned Abs, Butts and Thighshttps://practicaldermatology.com/news/meet-trusculpt-flex-cuteras-solution-for-toned-abs-butts-and-thighs/2460084/Cutera is launching the new truSculpt flex, muscle sculpting platform in the United States, and commercial shipments are slated to begin immediately. truSculpt flex is FDA-cleared for the indications of the improvement of abdominal tone, strengt
- Phase 3b/4 Study ANSWERs Rosacea Therapy Questionshttps://practicaldermatology.com/news/phase-3b4-study-answers-rosacea-therapy-questions/2460082/Results of the phase 3b/4 ANSWER study, recently published onlinein the Journal of the American Academy of Dermatology, show that concomitant use of Oracea Capsules and Soolantra Cream provided significan
- SENTÉ Names Adelle Walker as Chief Marketing Officerhttps://practicaldermatology.com/news/sente-names-adelle-walker-as-chief-marketing-officer/2460080/SENTÉ® has appointed Adelle Walker Chief Marketing Officer. As Chief Marketing Officer (CMO), she will take an executive leadership role in defining pipeline strategy along with internal and external portfolio planning. Her commercialization leadership will span across all fa
- Dominion Aesthetic Technologies, Inc.’s eon FR Scores FDA Nodhttps://practicaldermatology.com/news/dominion-aesthetic-technologies-incs-eon-fr-scores-fda-nod/2460077/The FDA has cleared Dominion Aesthetic Technologies, Inc
- AbbVie to Acquire Allerganhttps://practicaldermatology.com/news/abbvie-to-acquire-allergan/2460076/AbbVie Inc. and Allergan plc have entered into a definitive transaction agreement under which AbbVie will acquire Al
- FDA Clears Allergan's CoolTone Devicehttps://practicaldermatology.com/news/fda-clears-allergans-cooltone-device/2460075/The FDA has cleared Allergan plc's CoolTone device for improvement of abdominal tone, strengthening of the abdominal muscles, and development for firmer abdomen. CoolTone is also indicated for strengthening, toning and firming of buttocks and thighs. “By partnering with A
- Proactiv Works to Change the Conversation about Acne with New Initiativeshttps://practicaldermatology.com/news/proactiv-works-to-change-the-conversation-about-acne-with-new-initiatives/2460072/Proactiv is taking on the acne positivity movement with new initiatives aimed to help validate the emotional journey of people with acne and inspire compassion for others. As part of these initiatives, Brand Ambassador Kendall Jenner will continue
- Lilly: Taltz Tops Adalimumab for PsA in Head-to-Headhttps://practicaldermatology.com/news/lilly-taltz-tops-adalimumab-for-psa-in-head-to-head/2460069/Results of the phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriatic arthritis (PsA), presented as a late-breaking abstract at the European Congress of Rheumatology (EULAR) in Madrid, show that a significantly higher proportion of patients met the primary end
- Novartis: New Data Show Cosentyx Has Durable Response Across Psoriatic Diseasehttps://practicaldermatology.com/news/novartis-new-data-show-cosentyx-has-durable-response-across-psoriatic-disease/2460068/A new comprehensive analysis shows the long-term efficacy and safety of secukinumab in multiple manifestations of psoriatic disease, including moderate-to-severe plaque-type, nail and palmoplantar psoriasis, psoriatic arthritis and ankylosing spondylitis. Data are derived from key Phase 3, random
- Aclaris Therapeutics: Positive 6-Month Results from Phase 2 Open-Label Trial of Topical ATI-502 in Androgenetic Alopeciahttps://practicaldermatology.com/news/aclaris-therapeutics-positive-6-month-results-from-phase-2-open-label-trial-of-topical-ati-502-in-androgenetic-alopecia/2460067/Results from a Phase 2 open-label clinical trial of ATI-502 (AGA-201), an investigational topical Janus Kinase (JAK) 1/3 inhibitor are promising for patients with androgenetic alopecia (AGA). Aclaris Therapeutics announced the findings and says 12-month data should be available by year’s en